Microcap Ledger ProMIS Neurosciences Inc. $PMN
Facts as of . Built from SEC filings and our own data. Small caps move fast; check the latest filings.
Snapshot
- Exchange
- Nasdaq Capital Market
- Sector
- Pharmaceutical Preparations
- Headquarters
- Toronto, Ontario, Canada
- Fiscal year end
- December 31
- Shares outstanding
- 8,967,693 [10-Q 2026-08-13]
What the company doesAI summary of filing
ProMIS Neurosciences is a pre-revenue, clinical-stage biopharmaceutical company that develops monoclonal antibodies and other therapies targeting misfolded proteins in neurodegenerative diseases. The company uses its proprietary EpiSelect computational platform to identify disease-specific epitopes on toxic misfolded proteins and generate selective antibody therapeutics. Its lead candidate, PMN310, is in Phase 1b clinical trials for Alzheimer's disease, with additional programs in earlier stages targeting amyotrophic lateral sclerosis (PMN267), and synucleinopathies including Parkinson's disease, dementia with Lewy bodies, and multiple system atrophy (PMN442). The company has no approved products, generates no product revenue, and has incurred losses since inception. [10-K 2026-03-25]
Financial health
| Period | Revenue | Net income | Operating cash flow | Cash | Filing |
|---|---|---|---|---|---|
| 6 months to Jun 2026 | — | −$19.97M | −$22.77M | $53.43M | [10-Q 2026-08-13] |
| FY ended Dec 2025 | — | −$39.72M | −$28.12M | $6.12M | [10-K 2026-03-25] |
| FY ended Dec 2024 | — | $2.78M | −$27.18M | $13.29M | [10-K 2026-03-25] |
- Quarterly cash burn
- −$11.38M
- Cash runway Estimate
- ~14.1 months
Capital structure and dilution
| Date | Shares outstanding | Filing |
|---|---|---|
| 2024-11-14 | 32,689,190 | [10-Q 2024-11-14] |
| 2025-03-29 | 32,689,190 | [10-K 2025-03-31] |
| 2025-05-12 | 32,689,190 | [10-Q 2025-05-12] |
| 2025-08-13 | 51,806,497 | [10-Q 2025-08-13] |
| 2025-11-12 | 53,811,110 | [10-Q 2025-11-12] |
| 2026-03-25 | 8,967,693 | [10-K 2026-03-25] |
| 2026-05-12 | 8,967,693 | [10-Q 2026-05-12] |
| 2026-08-13 | 8,967,693 | [10-Q 2026-08-13] |
- Shelf registration
- S-3 filed 2026-03-25; declared effective 2026-04-02 [S-3 2026-03-25]
Listing status
Current status: 1 Form 8-K Item 3.01 filing(s) in the last 24 months, most recent 2025-01-08. Item 3.01 covers delisting notices, failures to meet a listing rule and listing transfers; read the filing for which one.
| Date | Event | Details | Deadline | Filing |
|---|---|---|---|---|
| 2025-01-08 | 8-K Item 3.01 | Notice of delisting or failure to satisfy a continued listing rule or standard; or transfer of listing | — | [8-K 2025-01-08] |
Who owns it
| Date | Insider | Type | Shares | Price | Filing |
|---|---|---|---|---|---|
| 2026-08-05 | Kaplan Johanne | buy | 2,280 | $13.30 | [4 2026-08-07] |
Catalysts and calendar
| Date | Type | Title |
|---|---|---|
| 2026-08-14 | 13G/A | Beneficial ownership report (5%+ holder) |
| 2026-08-13 | 13G/A | Beneficial ownership report (5%+ holder) |
| 2026-08-13 | 8-K | Results of operations |
| 2026-08-13 | 10-Q | Quarterly report |
| 2026-08-13 | 13G/A | Beneficial ownership report (5%+ holder) |
| 2026-07-28 | 8-K | Regulation FD disclosure; Other events |
| 2026-05-20 | 8-K | Director or officer change; Shareholder vote results |
| 2026-05-15 | 13G | Beneficial ownership report (5%+ holder) |
| 2026-05-15 | 13G | Beneficial ownership report (5%+ holder) |
| 2026-05-12 | 10-Q | Quarterly report |
| 2026-05-12 | 8-K | Results of operations |
| 2026-05-07 | 13G/A | Beneficial ownership report (5%+ holder) |
Alerts for $PMN
Email me when ProMIS Neurosciences Inc. files an offering, gets a deficiency notice, or moves sharply.
Facts as of . Small caps move fast; check the latest filings.